Loading candles…
Windlas Biotech Ltd operates in the pharmaceutical and contract development and manufacturing organization (CDMO) industries. It functions as a CDMO specializing in manufacturing solid and liquid pharmaceutical dosage forms. Its product range includes oral solid formulations such as tablets, capsules, and sachets, complex generics, and health supplements. The company offers a broad spectrum of CDMO services encompassing product discovery, development, and commercial manufacturing of generic products. Windlas Biotech serves both domestic (India) and international business-to-business markets through its three main business segments: Generic Formulations CDMO, Trade Generics & Institutional, and Exports. No information on incorporation, founders, key management, subsidiaries, or listing exchanges is provided.
This page is a live market overview for WINDLAS BIOTECH LIMITED (WINDLAS) on the NSE. As a listed security, WINDLAS BIOTECH LIMITED is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for WINDLAS before placing trades on tick2trade.
As of the latest feed, WINDLAS last traded at ₹882.85 on NSE, up ₹9.1 (1.04%) from the previous close of ₹873.75. Today's session range is ₹861.8 – ₹888.45, against a 52-week band of ₹697.4 – ₹1,097.9. Traded volume today stands at 59.52K shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for WINDLAS in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether WINDLAS is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for WINDLAS BIOTECH LIMITED before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in WINDLAS. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated WINDLAS option chain page linked from this overview.
| Results - FY26 | To consider and approve the financial results for the period ended Jun 30, 2026 | 10 Aug 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 and dividend | 21 May 2026 |
| Buyback | To consider buyback for equity shares | 17 Apr 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 5 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 6 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 12 Aug 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 and recommend dividend, if any. | 22 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.